Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 18, Issue 7, Pages E232-E234Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1469-0691.2012.03820.x
Keywords
Indonesia; Plasmodium vivax malaria; primaquine; relapse; Solomon Islands
Categories
Funding
- Parasitic Disease Laboratory of the Taiwan Centers for Disease Control (Taipei, Taiwan)
Ask authors/readers for more resources
Clin Microbiol Infect 2012; 18: E232E234 Abstract Taiwan CDC investigated four cases of recurrent imported vivax malaria during 20032010. Molecular genotyping results and the lack of inter-episodes travel history indicated that two of the patients, who acquired vivax malaria in Indonesia and the Solomon Islands, respectively, suffered relapses after an interval of 34 months, despite completing standard-dose primaquine therapy (30 mg/day for 14 days) for the first episode. Treatment with a higher dose of primaquine (60 mg/day for 14 days) prevented further relapse in both patients. This finding calls for further monitoring of the therapeutic efficacy of primaquine in treating Plasmodium vivax acquired in southeast Asia and Oceania.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available